CDXS

Codexis Inc

Add to Watchlist

Advanced Chart

3.110

-0.13(-4.012%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

3.230

Open

3.230

VWAP

3.08

Vol

1.45M

Mkt Cap

257.65M

Low

3.010

Amount

4.49M

EV/EBITDA(TTM)

Total Shares

70.56M

245.28M

EV/OCF(TTM)

P/S(TTM)

5.12

Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

24.80M

+15.58%

-0.083

-36.54%

19.03M

+48.33%

-0.113

-61.21%

14.18M

+77.68%

-0.152

-52.49%

Estimates Revision

The market is revising Downward the revenue expectations for Codexis, Inc. (CDXS) for FY2025, with the revenue forecasts being adjusted by -0.29% over the past three months. During the same period, the stock price has changed by 33.48%.

Revenue Estimates for FY2025

Revise Downward

-0.29%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-2.59%

In Past 3 Month

Stock Price

Go Up

+33.48%

In Past 3 Month

5 Analyst Rating

89.07% Upside

Wall Street analysts forecast CDXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDXS is 5.88 USD with a low forecast of 3.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

1 Hold

0 Sell

Strong Buy

89.07% Upside

Current: 3.110

Low

3.00

Averages

5.88

High

11.00

89.07% Upside

Current: 3.110

Low

3.00

Averages

5.88

High

11.00

Cantor Fitzgerald

Kristen Kluska

Buy

Reiterates

$11

2024-11-22

Reason

Cantor Fitzgerald

Kristen Kluska

Price Target

$11

2024-11-22

Reiterates

Buy

Reason

Cantor Fitzgerald

Kristen Kluska

Buy

Reiterates

$11

2024-11-15

Reason

Cantor Fitzgerald

Kristen Kluska

Price Target

$11

2024-11-15

Reiterates

Buy

Reason

Benchmark

Robert Wasserman

Hold

Reiterates

n/a

2024-11-04

Reason

Benchmark

Robert Wasserman

Price Target

n/a

2024-11-04

Reiterates

Hold

Reason

Cantor Fitzgerald

Kristen Kluska

Buy

Reiterates

$11

2024-09-20

Reason

Cantor Fitzgerald

Kristen Kluska

Price Target

$11

2024-09-20

Reiterates

Buy

Reason

Cantor Fitzgerald

Kristen Kluska

Buy

Reiterates

$11

2024-08-29

Reason

Cantor Fitzgerald

Kristen Kluska

Price Target

$11

2024-08-29

Reiterates

Buy

Reason

Benchmark

Robert Wasserman

Strong Buy

Hold

Downgrades

n/a

2024-08-19

Reason

Benchmark

Robert Wasserman

Price Target

n/a

2024-08-19

Downgrades

Strong Buy

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Codexis Inc (CDXS.O) is -6.51, compared to its 5-year average forward P/E of -28.12. For a more detailed relative valuation and DCF analysis to assess Codexis Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-28.12

Current PE

-6.51

Overvalued PE

3.32

Undervalued PE

-59.57

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-23.42

Current EV/EBITDA

-6.08

Overvalued EV/EBITDA

6.47

Undervalued EV/EBITDA

-53.30

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

7.18

Current PS

3.72

Overvalued PS

12.16

Undervalued PS

2.19

Financials

Annual

Quarterly

FY2025Q1

YoY :

-55.82%

7.54M

Total Revenue

FY2025Q1

YoY :

+72.33%

-20.49M

Operating Profit

FY2025Q1

YoY :

+79.82%

-20.69M

Net Income after Tax

FY2025Q1

YoY :

+56.25%

-0.25

EPS - Diluted

FY2025Q1

YoY :

+68.79%

-15.05M

Free Cash Flow

FY2025Q1

YoY :

-10.87%

63.78

Gross Profit Margin - %

FY2025Q1

YoY :

+64.49%

-120.14

FCF Margin - %

FY2025Q1

YoY :

+306.99%

-274.27

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

6.4M

USD

Months

3-6

1.8M

USD

Months

6-9

447.4K

USD

Months

0-12

3.8M

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

607.2K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

6.4M

USD

Months

3-6

1.8M

USD

Months

6-9

447.4K

USD

Months

0-12

3.8M

USD

Months

CDXS News & Events

Events Timeline

2025-05-22 (ET)

2025-05-22

07:06:14

Codexis presents data on ECO Synthesis platform at TIDES USA meeting

2025-05-20 (ET)

2025-05-20

08:03:23

Aligos Therapeutics appoints Laura Kavanaugh as VP, head of legal

2025-05-14 (ET)

2025-05-14

16:13:24

Codexis sees FY25 revenue $64M-$68M, consensus $65.67M

News

3.5

05-22Newsfilter

Codexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA

9.5

05-14NASDAQ.COM

CODEXIS Earnings Results: $CDXS Reports Quarterly Earnings

9.5

05-12NASDAQ.COM

Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates